These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 23871661

  • 1. Comparison of dose-escalated, image-guided radiotherapy vs. dose-escalated, high-dose-rate brachytherapy boost in a modern cohort of intermediate-risk prostate cancer patients.
    Marina O, Gustafson GS, Kestin LL, Brabbins DS, Chen PY, Ye H, Martinez AA, Ghilezan MI, Wallace M, Krauss DJ.
    Brachytherapy; 2014; 13(1):59-67. PubMed ID: 23871661
    [Abstract] [Full Text] [Related]

  • 2. Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer.
    Mohammed N, Kestin L, Ghilezan M, Krauss D, Vicini F, Brabbins D, Gustafson G, Ye H, Martinez A.
    Int J Radiat Oncol Biol Phys; 2012 Jan 01; 82(1):204-12. PubMed ID: 21167653
    [Abstract] [Full Text] [Related]

  • 3. Randomised Phase II Feasibility Trial of Image-guided External Beam Radiotherapy With or Without High Dose Rate Brachytherapy Boost in Men with Intermediate-risk Prostate Cancer (CCTG PR15/ NCT01982786).
    Vigneault E, Morton G, Parulekar WR, Niazi TM, Springer CW, Barkati M, Chung P, Koll W, Kamran A, Monreal M, Ding K, Loblaw A.
    Clin Oncol (R Coll Radiol); 2018 Sep 01; 30(9):527-533. PubMed ID: 29903505
    [Abstract] [Full Text] [Related]

  • 4. An age-corrected matched-pair study of erectile function in patients treated with dose-escalated adaptive image-guided intensity-modulated radiation therapy vs. high-dose-rate brachytherapy for prostate cancer.
    Marina O, Warner J, Ye H, Grills IS, Shah C, Wallace M, Gustafson GS, Brabbins DS, Martinez AA, Krauss DJ.
    Brachytherapy; 2014 Sep 01; 13(2):163-8. PubMed ID: 24295963
    [Abstract] [Full Text] [Related]

  • 5. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.
    Martinez AA, Kestin LL, Stromberg JS, Gonzalez JA, Wallace M, Gustafson GS, Edmundson GK, Spencer W, Vicini FA.
    Int J Radiat Oncol Biol Phys; 2000 May 01; 47(2):343-52. PubMed ID: 10802358
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes.
    Olarte A, Cambeiro M, Moreno-Jiménez M, Arbea L, Pérez-Gracia JL, Gil-Bazo I, Pascual I, Aristu J, Martínez-Monge R.
    Brachytherapy; 2016 May 01; 15(2):127-35. PubMed ID: 26832677
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Four-year outcomes of hypofractionated high-dose-rate prostate brachytherapy and external beam radiotherapy.
    Chen WC, Tokita KM, Ravera J, Fu P, Jiang Y, Kaminsky DA, Ponsky L, Ellis RJ.
    Brachytherapy; 2013 May 01; 12(5):422-7. PubMed ID: 23380382
    [Abstract] [Full Text] [Related]

  • 12. A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients.
    Joseph N, Taylor C, O'Hara C, Choudhury A, Elliott T, Logue J, Wylie J.
    Radiother Oncol; 2016 Nov 01; 121(2):299-303. PubMed ID: 28029404
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Decreased acute toxicities of intensity-modulated radiation therapy for localized prostate cancer with prostate-based versus bone-based image guidance.
    Nakamura K, Mizowaki T, Inokuchi H, Ikeda I, Inoue T, Kamba T, Ogawa O, Hiraoka M.
    Int J Clin Oncol; 2018 Feb 01; 23(1):158-164. PubMed ID: 28756594
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Five-Year Outcomes of a Single-Institution Prospective Trial of 19-Gy Single-Fraction High-Dose-Rate Brachytherapy for Low- and Intermediate-Risk Prostate Cancer.
    Siddiqui ZA, Gustafson GS, Ye H, Martinez AA, Mitchell B, Sebastian E, Limbacher A, Krauss DJ.
    Int J Radiat Oncol Biol Phys; 2019 Aug 01; 104(5):1038-1044. PubMed ID: 30771408
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.
    Morris WJ, Tyldesley S, Rodda S, Halperin R, Pai H, McKenzie M, Duncan G, Morton G, Hamm J, Murray N.
    Int J Radiat Oncol Biol Phys; 2017 Jun 01; 98(2):275-285. PubMed ID: 28262473
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.